May 8, 2018

Home

LYNDRA THERAPEUTICS

TRANSFORMING THE WAY WE TAKE MEDICINE FOR A HEALTHIER WORLD
Lyndra Therapeutics Announces Notice of Allowance on Patent Covering Long-acting Pill
Icon Image

Our Vision

Ultra-long-acting oral medicines will remove the burden of daily pills and improve compliance, health, and quality of life for patients and caregivers.

Icon Image

Our Approach

Human nature is a hard thing to change. At Lyndra, we’ve turned the problem on its head. We ask, “What if we stopped trying to change the patient, and changed the pill instead?

Icon Image

Our Therapies

Our ultra-long-acting oral medicines provide better health outcomes and quality of life, reduced side effects, improved drug efficacy, slowed spread of disease, and lower health costs.

Ultra-Long-Acting Oral Dosing is Achievable

Our Team has developed the first ultra-long-acting pill that lasts a week or longer and can provide a wide range of medicines in a familiar oral capsule form. Once inside the stomach, the capsule delivers steady amounts of medicine for seven days or more.  Our once-weekly product has safely demonstrated gastric residence with predictable pharmacokinetics in humans.  There are no other oral products which provide ultra-long-acting therapeutic coverage or a controlled, steady delivery of medicine which can reduce side effects and improve drug efficacy, resulting in measurable health outcomes.

  • Advantages in systemic, non-systemic, and local target delivery due to continuous & steady delivery
  • Possibility of reducing total dose while maintaining efficacy (non-inferiority)
  • Reducing Cmax can improve side effects
  • Forgiveness if delayed administration

  • Reduced healthcare costs through better pharmacology and measurable health outcomes
  • Patient freedom form the burden of daily medications

  • Adaptable for wide range of single agents (small molecule / peptide) and combinations
  • Discreet user controlled administration
  • Reduced pill burden
  • Reduced caregiver burden

  • Superior Pharmacology for existing Agents
  • Loss of Exclusivity (LOE)
  • Combination Products
  • Local GI Delivery
  • Non-systemic Delivery Enhanced Continuous Release

"Extended-release oral systems will revolutionize current clinical-care models and maximize effective treatment for a wide range of diseases in a variety of clinical settings."​

Robert Langer & Giovanni Traverso